Flagship Pioneering — 2015 Investments
3 investments dated 2015 · listed companies and verified rows first · show all
BG Medicine develops the BGM Galectin-3 test, a diagnostic blood test marker used in the assessment of cardiac fibrosis.
BiotechHealthtechMedical DevicesWaltham, US
Stephen Hall(Executive Officer)Paul Sohmer(Executive Officer, Director)Aram Adourian(Executive Officer)Harry Wilcox(Director)
BoardTimothy Harris(Director)
Board seatNoubar Afeyan· per SEC Form D · $2.5M raise · filed May 2015
Cambridge, MA clinical-stage biotech developing engineered exosome therapeutics; IPO'd on NASDAQ in 2020, later restructured.
BiotechSeattle, US
Doug Williams(Executive Officer, Director)
BoardSteven Gillis(Director)Eric Lander(Director)
Board seatNoubar Afeyan· per SEC Form D · filed Nov 2015
Co-investorsARCH Venture PartnersEcoR1 Capital
BiotechCambridge, US
Robert Connelly(Executive Officer, Director)Garry Menzel(Executive Officer)Jeff Moore(Executive Officer)
BoardJohn Mendlein(Director)
Board seatDavid BerryNoubar Afeyan· per SEC Form D · filed Feb 2016
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.